Pharmacology
ACE Inhibitors for OPRA: Mechanism, Counselling, Monitoring and MCQs
A focused, exam-oriented rundown of ACE inhibitors — the mechanism detail OPRA actually tests, the side effects and monitoring that show up in scenarios, and the counselling points that get asked about directly.
Why this topic matters
ACE inhibitors are a foundation drug class that reappears across hypertension, heart failure, diabetic nephropathy and post-MI scenarios — understanding the mechanism properly (not just the name) is what lets you correctly reason through side effects and interactions you haven't seen before.
Learning objectives
- Explain the mechanism of ACE inhibitors and link it to their major side effects
- List key indications beyond hypertension
- Identify monitoring requirements and important drug interactions
- State the counselling points most likely to appear in an OPRA scenario
Core concepts
Mechanism
ACE inhibitors block angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction and aldosterone-driven sodium/water retention, and — because ACE also breaks down bradykinin — leads to bradykinin accumulation, which is the mechanism behind the characteristic dry cough and the (rare but serious) risk of angioedema.
Indications and typical dosing
- Hypertension — e.g. perindopril 2.5–5 mg daily, ramipril 2.5–5 mg daily, enalapril 5–10 mg daily (usual maintenance ranges; start low, particularly in older or volume-depleted patients)
- Heart failure with reduced ejection fraction — started at a low dose and up-titrated over weeks under monitoring
- Post-myocardial infarction (cardioprotection)
- Diabetic nephropathy / proteinuric chronic kidney disease (renoprotection, independent of blood-pressure effect)
Clinical application
Reading a side-effect back to the mechanism
A persistent dry cough or sudden facial/lip swelling in a patient on an ACE inhibitor both trace back to bradykinin accumulation — recognising that link is often faster than trying to recall the side effect as an isolated fact.
Monitoring and counselling in practice
Check baseline renal function, electrolytes and blood pressure before starting, then recheck within 1–2 weeks of initiation or a dose increase — sooner in patients with pre-existing renal impairment, heart failure, or those also on a diuretic or NSAID. Three counselling points come up repeatedly:
- First-dose hypotension risk (higher starting doses, heart failure, volume depletion): take the first dose at bedtime.
- Avoid potassium supplements and salt substitutes — many salt substitutes are potassium chloride-based and compound hyperkalaemia risk.
- Red flag: swelling of the face, lips or tongue, or difficulty breathing — seek urgent medical attention (possible angioedema).
Common mistakes
- Confusing the ACE-inhibitor cough (bradykinin-mediated, common, not dangerous) with angioedema (also bradykinin-mediated, but rare and potentially life-threatening) — they need very different responses.
- Not checking potassium before and after initiation, particularly in patients also on potassium-sparing diuretics or with renal impairment.
- Forgetting the absolute contraindication in pregnancy.
- Missing the interaction with NSAIDs, which can blunt the antihypertensive effect and increase renal risk (the classic "triple whammy" with a diuretic).
Exam tips
- • If the stem mentions a switch to an ARB after an ACE-inhibitor-induced cough, that's testing whether you know ARBs don't share the bradykinin-mediated cough (they act on the receptor, not the enzyme).
- • Angioedema on an ACE inhibitor is a stop-and-do-not-rechallenge scenario, including avoiding ARBs immediately afterward in most guidance — watch for this as a distractor where an ARB switch is wrongly offered as safe.
Memory tricks
- • "-pril = bradykinin still" — the -pril suffix keeps bradykinin around, giving the cough; ARBs (-sartan) don't touch bradykinin, so no cough.
Clinical pearls
- 💡 The NSAID + ACE inhibitor/ARB + diuretic combination ("triple whammy") is a well-recognised acute kidney injury risk pattern and a favourite scenario setup for testing interaction recognition.
Tables
ACE inhibitor vs. ARB — key differences
| Feature | ACE inhibitor | ARB |
|---|---|---|
| Mechanism | Blocks ACE enzyme | Blocks angiotensin II receptor |
| Bradykinin effect | Accumulates (causes cough) | Unaffected |
| Cough | Common | Rare |
| Angioedema risk | Present | Present, lower incidence |
| Pregnancy | Contraindicated | Contraindicated |
Practice MCQs (100% original)
1. A patient develops a persistent dry cough two months after starting perindopril. What is the most likely underlying mechanism?
2. A patient taking ramipril and spironolactone for heart failure has a routine potassium of 5.8 mmol/L. What is the most appropriate immediate action?
3. A patient who developed angioedema on enalapril is being considered for an alternative antihypertensive. Which class should generally be avoided immediately afterward due to shared risk?
Ready to practise this topic?
Try original OPRA-style questions with detailed, option-by-option explanations — free to start.
Start freeFrequently asked questions
Why do ACE inhibitors cause a dry cough but ARBs don't?
ACE inhibitors block the enzyme that also breaks down bradykinin, so bradykinin accumulates and triggers a cough in some patients. ARBs act at the angiotensin II receptor rather than the ACE enzyme, so bradykinin metabolism is unaffected and the cough is far less common.
Can ACE inhibitors be used in pregnancy?
No — ACE inhibitors are contraindicated throughout pregnancy due to the risk of fetal renal impairment and other adverse outcomes.
Official references
- Australian Medicines Handbook — ACE inhibitors ↗ — Class monograph: mechanism, dosing, monitoring
- Therapeutic Guidelines Australia — Cardiovascular ↗ — Indication-specific place in therapy